Paul Hartmann AG (PHH2) Fair Value & Analysis
Healthcare · DE · Market cap €710M
Strengths
Risks
Fair value as of: Aug 20, 2026
From 24 valuation models · updated yesterday
Share price +0.5% over the past month.
A solid business, screening 31% undervalued on our models.
What matters now
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (€200.75 to €399.68) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range €159.58 – €314.46 · fair‑value band €200.75 – €399.68 · the €200.00 price screens below the €261.49 fair value. Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Paul Hartmann AG (PHH2) currently trades at €200.00, while our model-based Fair Value estimate is €261.49, implying the stock looks roughly 30.8% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Paul Hartmann AG generated revenue of €2.5B at a net margin of 4.0%. Revenue grew 3.1% year over year. It earns a return on equity of 8.6%. Net debt stands at €105M. Fundamentals as of Aug 20, 2026
Our scenario range runs from €200.75 (bear case) to €399.68 (bull case); at €200.00, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 31%, PHH2 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (€344.55) versus Growth DCF (€75.39). Highest evidence: Growth DCF (80).
Notify me when PHH2 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management.
Full company description
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management. It offers absorbent underwear, incontinence pads and pants, and fixation pants; medical skincare products; wound management products, such as hydro active wound and silicone SAP dressings, post-op dressings, nature care, adhesive fixation, non-adhesive fixation, gauze, sponges/tamponades, contact layers, absorption pads, cotton, and negative pressure wound therapy; compression, universal, zinc paste, and padding bandages; and hands, skin, surface, instruments, and equipment disinfection and hygiene products. In addition, the company sells operating theater products, including surgical drapes, operating theater clothing, surgical gloves, surgical absorbents and instruments; various Mediset products; patient care products, such as hygiene and maternity products, examination gloves, and nursing care products; diagnostics, such as blood pressure monitors, scale, and thermometers; first aid products; and cotton wool and cosmetic products. It sells its products under the CombiSet, DermaPlast, MoliCare, Sterillium, Veroval, and Zetuvit brands. Paul Hartmann AG was founded in 1818 and is headquartered in Heidenheim, Germany.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Paul Hartmann AG reported revenue of €2.4B in FY2025 versus €2.3B in FY2021, a compound +1.6%/yr. Reported net income was €61.2M in FY2025, compounding −10.3%/yr from FY2021.
Watch PHH2: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $182.09 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 435.80 | kr 382.22 | -12% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Paul Hartmann AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Paul Hartmann AG (PHH2) overvalued or undervalued?
What is the fair value of PHH2?
What is the quality score of PHH2?
What is the revenue of Paul Hartmann AG (PHH2)?
What is the net profit margin of PHH2?
Does Paul Hartmann AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Paul Hartmann AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.